



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# MEDICAMEN ORGANICS LIMITED

CORPORATE IDENTITY NUMBER: U74899DL1995PLC066416

Our Company was incorporated on March 15, 1995 as 'Panchdeep Pharmaceuticals Limited', a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of our Company was changed to 'Medicamen Organics Limited' and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. For details relating to change in the Registered Office of our Company, please refer to "History and Certain Corporate Matters" on page 135 of the RHP.

Registered Office: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India

Contact Number: +91-9818222845; Website: www.medicamenorganics.com;

Contact Person: Ms. Varsha Bansal; E-mail Id: cs@mediorganics.in;

## OUR PROMOTERS: MR. BAL KISHAN GUPTA AND MR. ASHUTOSH GUPTA

INITIAL PUBLIC OFFER OF UPTO 31,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MEDICAMEN ORGANICS LIMITED (THE "COMPANY" OR "MEDICAMEN" OR "ISSUER") AT AN ISSUE PRICE OF ₹ [\*] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [\*] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ [\*] LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [\*] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [\*] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 29,28,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [\*] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [\*] LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.49 % AND 25.02 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

• QIB PORTION: NOT MORE THAN 50.00% OF THE NET ISSUE • RETAIL PORTION: NOT LESS THAN 35.00% OF THE NET ISSUE

• NON-INSTITUTIONAL PORTION: NOT LESS THAN 15.00% OF THE NET ISSUE • MARKET MAKER PORTION: UP TO 1,72,000 EQUITY SHARES OR 5.54% OF THE ISSUE

**PRICE BAND: ₹ 32 TO ₹ 34 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH**

**THE FLOOR PRICE IS 3.2 TIMES OF THE FACE VALUE AND THE CAPPRICE IS 3.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARES. BIDS CAN BE MADE FOR A MINIMUM OF 4,000 EQUITY SHARES AND IN MULTIPLES OF 4,000 EQUITY SHARES THEREAFTER.**

### RISKS TO INVESTORS

- We require a number of approvals, licenses, registrations and permits in the ordinary course of our business and any failure or delay in obtaining the same in a timely manner may adversely affect our operations.
- The Merchant Banker associated with the Issue has handled 25 public issues in the past two years out of which no issues closed below the Issue Price on Listing date
- Our Company's failure to maintain the quality standards of the products or keep pace with the technological developments could adversely impact our business, results of operations and financial condition.
- The Price/ Earnings ratio based on Diluted EPS for year ended March 2024 for the company at the upper end of the Price Band is 10.69.
- Weighted Average Return on Net worth for Fiscals 2024, 2023 and, 2022 is 11.72%

## BID/ISSUE PROGRAM

**ANCHOR INVESTOR BIDDING DATE<sup>(1)</sup>: THURSDAY, JUNE 20, 2024**

**BID/ ISSUE OPENS ON<sup>(1)</sup>: FRIDAY, JUNE 21, 2024**

**BID/ ISSUE CLOSES ON: TUESDAY, JUNE 25, 2024**

<sup>(1)</sup>Our Company in consultation with the BRLM may consider participation by Anchor Investors. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/ Issue Opening Date in accordance with the SEBI (ICDR) Regulations, 2018.

In case of any revisions in the Price Band, the Bid/ Issue Period will be extended by at least three additional working days after such revision of the Price Band, subject to the Bid/ Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum of three Working Days, subject to the Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 216 of the Red Herring Prospectus.

Bidders/Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active.

**CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS:** For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 135 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page 257 of the Red Herring Prospectus.

**LIABILITY OF MEMBERS AS PER MOA:** The Liability of the members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.

**AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE:** The Authorized share Capital of the Company is Rs. 14,00,00,000/- (Rupees Fourteen Crore only) divided into 1,40,00,000 (One Crore forty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each. For details of the Capital Structure, see "Capital Structure" on the page 62 of the Red Herring Prospectus.

**NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:** Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: 100 equity shares were subscribed by Bal Kishan Gupta, 100 equity shares were subscribed by Lakhwinder Singh Arora, 100 equity shares were subscribed by Virender Kumar, 100 equity shares were subscribed by Ranjit Singh, 100 equity shares were subscribed by Anand Kumar Razdan, 100 equity shares were subscribed by Ashok Nayyar, 100 equity shares were subscribed by Shila Gupta, 100 equity shares were subscribed by Gurnarhan Arora, and 100 equity shares were subscribed by Tarlochan Singh Sarma of Rs 10/- each. Details of the main objects of the Company as contained in the Memorandum of Association, see "History and Corporate Structure" on page 135 of the Red Herring Prospectus. For details of the share capital and capital structure of the Company see "Capital Structure" on page 62 of the Red Herring Prospectus.

**LISTING:** The Equity Shares issued through the Red Herring Prospectus are proposed to be listed on the NSE EMERGE (SME Platform of NSE). Our Company has received an 'in-principle' approval from the NSE for the listing of the Equity Shares pursuant to letter dated June 10, 2024. For the purpose of the Issue, the Designated Stock Exchange shall be NSE Limited (NSE). A signed copy of the Red Herring Prospectus has been delivered for registration to the ROC on June 13, 2024 and Prospectus shall be delivered for filing to the RoC in accordance with Section 26(4) of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/ Issue Closing Date, see "Material Contracts and Documents for Inspection" on page 257 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"):** Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI on page 196 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE):** It is to be distinctly understood that the permission given by NSE EMERGE ("EMERGE Platform of NSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by NSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE.

**GENERAL RISK:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to 'Risk Factors' on page 27 of the Red Herring Prospectus.

### ASBA\*

Simple, Safe, Smart way of Application- Make use of it!!!

\*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.

Mandatory in Public Issues from January 01, 2016. No cheque will be accepted



UPI-Now available in ASBA for Retail Individual Investors (RII)\*\*

Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Retail Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 216 of the Red Herring Prospectus. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.

\*ASBA forms can be downloaded from the website of NSE EMERGE ("SME Portal of NSE")

\*\*List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. AXIS BANK Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll free number-18001201740 and Mail Id- ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in. For issue related grievance investors may contact: GYR Capital Advisors Private Limited - Mr. Mohit Baid (+91 87775 64648) (Email id: investors@gyrcapitaladvisors.com).

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
<p><b>GYR CAPITAL ADVISORS PRIVATE LIMITED</b> 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad-380 054, Gujarat, India. Telephone: +91 87775 64648 Facsimile: N.A. E-mail: info@gyrcapitaladvisors.com Website: www.gyrcapitaladvisors.com Investor grievance: investors@gyrcapitaladvisors.com Contact Person: Mohit Baid SEBI Registration Number: INM000012810</p>	<p><b>KFIN TECHNOLOGIES LIMITED</b> Selenium Tower- B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana, India. Tel No.: +91 40 6716 2222 Fax: +91 40 2343 1551 Website: www.kfintech.com Email: nvl.ipo@kfintech.com; Investor Grievance Email: einward_ris@kfintech.com Contact Person: Mr. M Murali Krishna SEBI Registration No.: INR000000221</p>	<p>Ms. Varsha Bansal, is the Company Secretary and Compliance Officer of our Company. His contact details are set forth hereunder: 10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, 110052, India. Telephone: +91-9818222845, Facsimile: N.A. E-mail: cs@mediorganics.in</p> <p>Investors can contact the Company Secretary and Compliance Officer or the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.</p>

**AVAILABILITY OF RED HERRING PROSPECTUS:** Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at https://www.medicamenorganics.com /investor-corner/, the website of the BRLM to the Issue at: www.gyrcapitaladvisors.com, the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents, respectively.

**AVAILABILITY OF BID-CUM-APPLICATION FORMS:** Bid-Cum-Application forms can be obtained from the Registered Office of the Company: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India; Telephone: +91-9818222845; BRLM: GYR Capital Advisors Private Limited, Telephone: +91 87775 64648 and the Sub Syndicate Member: Eureka Stock & Share Broking Services Limited, Telephone: 033 66280000 (131) and the Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the website of NSE EMERGE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

**ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK:** AXIS BANK LIMITED

**UPI:** Retail Individual Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

Place: Delhi  
Date: June 14, 2024

On behalf of Board of Directors  
For MEDICAMEN ORGANICS LIMITED  
Sd/-  
Ms. Varsha Bansal  
Company Secretary & Compliance Officer

**Disclaimer:** MEDICAMEN ORGANICS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the RHP with the Registrar of Companies, Delhi and Haryana situated at Delhi on June 13, 2024 and thereafter with SEBI and the Stock Exchange. Full copy of the Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of the Company at https://www.medicamenorganics.com/investor-corner/, the website of the BRLM to the Issue at: www.gyrcapitaladvisors.com, the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 27 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

THE BUSINESS DAILY.

FINANCIAL EXPRESS

FOR DAILY BUSINESS.



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# MEDICAMEN ORGANICS LIMITED

Corporate Identity Number: U74899DL1995PLC066416

Our Company was incorporated on March 15, 1995 as 'Panchdeep Pharmaceuticals Limited', a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of our Company was changed to 'Medicamen Organics Limited' and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. For details relating to change in the Registered Office of our Company, please refer to "History and Certain Corporate Matters" on page 135 of this RHP.

Registered Office: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India  
Contact Number: +91-9818222845; Website: www.medicamenorganics.com;  
Contact Person: Ms. Varsha Bansal; E-mail Id: cs@mediorganics.in;

## OUR PROMOTERS: MR. BAL KISHAN GUPTA AND MR. ASHUTOSH GUPTA

INITIAL PUBLIC OFFER OF UPTO 31,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MEDICAMEN ORGANICS LIMITED (THE "COMPANY" OR "MEDICAMEN" OR "ISSUER") AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [-] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ [-] LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [-] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 29,28,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [-] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [-] LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.49% AND 25.02% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

• QIB PORTION: NOT MORE THAN 50.00% OF THE NET ISSUE • RETAIL PORTION: NOT LESS THAN 35.00% OF THE NET ISSUE

• NON-INSTITUTIONAL PORTION: NOT LESS THAN 15.00% OF THE NET ISSUE • MARKET MAKER PORTION: UP TO 1,72,000 EQUITY SHARES OR 5.54% OF THE ISSUE

## PRICE BAND: ₹ 32 TO ₹ 34 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH

THE FLOOR PRICE IS 3.2 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 3.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.  
BIDS CAN BE MADE FOR A MINIMUM OF 4,000 EQUITY SHARES AND IN MULTIPLES OF 4,000 EQUITY SHARES THEREAFTER.

### RISKS TO INVESTORS

- We require a number of approvals, licenses, registrations and permits in the ordinary course of our business and any failure or delay in obtaining the same in a timely manner may adversely affect our operations.
- The Merchant Banker associated with the Issue has handled 25 public issues in the past two years out of which no issues closed below the Issue Price on Listing date
- Our Company's failure to maintain the quality standards of the products or keep pace with the technological developments could adversely impact our business, results of operations and financial condition.
- The Price/ Earnings ratio based on Diluted EPS for year ended March 2024 for the company at the upper end of the Price Band is 10.69.
- Weighted Average Return on Net worth for Fiscals 2024, 2023 and, 2022 is 11.72%

### BASIS FOR ISSUE PRICE

The Issue Price will be determined by our Company in consultation with the Book Running Lead Manager on the basis of the assessment of market demand for the Equity Shares through the Book Building Process and on the basis of quantitative and Equity Qualitative factors as described below. The face value of the Equity Shares is Rs. 10 each and the Issue Price is 3.2 times the face value at the lower end of the Price Band and 3.4 times the face value at the higher end of the Price Band. Investors should also refer to "Our Business", "Risk Factors", "Financial Information" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" beginning on pages 101, 27, 160 and 165, respectively of the Red Herring Prospectus, to have an informed view before making an investment decision.

#### QUALITATIVE FACTORS

Some of the qualitative factors and our strengths which form the basis for computing the Issue Price are:

- Experienced Promoters and Management Team;
- Long standing relationships with customers;
- Efficient operational team;
- Consistent financial performance;

For further details, see "Our Business—Our Competitive Strengths" on page 104.

#### QUANTITATIVE FACTORS

The information presented in this section for the restated audited financial statements of the Company for the financial year ended March 31, 2024, 2023 and 2022 is derived from our Restated Financial Statements. For more details on financial information, investors please refer the chapter titled "Restated Financial Information" beginning on Page No. 160 of this Red Herring Prospectus.

Investors should evaluate our Company taking into consideration its earnings and based on its growth strategy. Some of the quantitative factors which may form the basis for computing the price are as follows:

#### 1. Basic & Diluted Earnings per share (EPS) (Face value of ₹ 10 each):

As per the Restated Financial Statements:

Year ended	Basic and Diluted EPS (in ₹) #	Weight
March 31, 2024	3.18	3
March 31, 2023	1.62	2
March 31, 2022	0.17	1
Weighted Average		2.15

#### Note:

##### 1. The ratios have been computed as below:

$$\text{Basic Earnings per Share (₹)} = \frac{\text{(Net profit/ (loss) as restated, attributable to Equity Shareholders)}}{\text{(Weighted average number of Equity Shares outstanding during the year/period)}}$$

$$\text{Diluted Earnings per Share (₹)} = \frac{\text{(Net profit/ (loss) as restated, attributable to Equity Shareholders)}}{\text{(Weighted average number of Diluted Equity Shares outstanding during the year/period)}}$$

##### 2. Price Earning (P/E) Ratio in relation to the Price Band of ₹ 32 to ₹ 34 per Equity Share of Face Value of ₹ 10/- each fully paid up:

Particulars	(P/E) Ratio at the Floor Price*	(P/E) Ratio at the Cap Price*
P/E ratio based on Basic and Diluted EPS as at March 31, 2024	10.07	10.70
P/E ratio based on Weighted Average EPS	14.84	15.77

\*Will be included in the Prospectus

##### 3. Industry Peer Group P/E ratio

Particulars	Industry P/E
Highest	3542.75
Lowest	4.72
Average	33.60

#### Notes:

- The industry high and low has been considered from the industry peer set provided above. The industry composite has been calculated as the arithmetic average P/E of the industry peer set disclosed above
- P/E Ratio has been computed based on the closing market price of equity shares on BSE on January 05, 2024, divided by the diluted EPS.
- All the financial information for listed industry peers mentioned above is sourced from the annual reports of the relevant companies for Fiscal 2023, as available on the websites of the Stock Exchanges.

##### 4. Return on Net worth (RoNW) #

Fiscal Year ended	RoNW (%)	Weight
March 31, 2024	15.83	3
March 31, 2023	10.79	2
March 31, 2022	1.27	1
Weighted Average (of the above three financial years)		11.72

Note: Return on Net worth has been calculated as per the following formula:

$$\text{RoNW} = \frac{\text{(Net profit/loss after tax, as restated)}}{\text{(Net worth excluding revaluation reserve)}}$$

Net worth is computed as the sum of the aggregate of paid up equity share capital, all reserves created out of the profits, securities premium account received in respect of equity shares and debit or credit balance of profit and loss account. It may be noted that equity component of financial instruments is excluded while calculating Net worth of the Company.

##### 5. Net Asset Value (NAV) per Equity Share (face value of ₹ 10/- each):

Particulars	NAV per equity share (₹)
As on March 31, 2024	17.66
As on March 31, 2023	14.97
After the Completion of the Issue:	
- At Floor Price	21.46
- At Cap Price	21.99
- At Issue Price (2)	[-]

#### Note:

Net Asset Value has been calculated as per the following formula:

$$\text{NAV} = \frac{\text{(Net worth excluding preference share capital and revaluation reserve)}}{\text{(Outstanding number of Equity shares at the end of the year/period)}}$$

Net worth is computed as the sum of the aggregate of paid up equity share capital, all reserves created out of the profits, securities premium account received in respect of equity shares and debit or credit balance of profit and loss account. It may be noted that equity component of financial instruments is excluded while calculating Net worth of the Company.

### 6. Comparison of Accounting Ratios with Industry Peers:

Name of the Company	Face Value (₹)	Current Market Price*	EPS (₹)		P/E Ratio*	RoNW (%)	Net Asset Value Per Share	Total Income (₹ in Lakhs)
			Basic	Diluted				
Medicamen Organics Limited (Our company)	10.00	[-]	3.18	3.18	[-]	15.23	17.66	2,528.96
<b>Peer Group</b>								
Brooks Laboratories Ltd	10.00	133.25	(12.57)	(12.57)	10.60	-28.26	30.10	6,340.80
Cian Healthcare Ltd	10.00	23.15	0.43	0.43	53.84	1.75	22.40	6,809.94
Zenotech Laboratories Ltd	10.00	73.64	1.90	1.90	38.76	14.08	14.20	4350.80

\*Source: All the financial information for listed industry peers mentioned above is sourced from the Annual Reports of the aforesaid companies for the year ended March 31, 2023 and stock exchange data dated February 19, 2024 to compute the corresponding financial ratios for the financial year ended March 31, 2023. The current market price and related figures are as on February 19, 2024.

i. The EPS, NAV, RoNW and Total Income of our company are taken as per Restated Financial Statement for the Financial year ended March 31, 2024.

ii. NAV per share is computed as the closing net worth divided by the weighted average number of paid-up equity shares as on March 31, 2024.

iii. RoNW has been computed as net profit after tax divided by closing net worth.

iv. Net worth has been computed in the manner as specified in Regulation 2(1) (hh) of SEBI (ICDR) Regulations, 2018.

v. The face value of Equity Shares of our company is ₹ 10/- per Equity Share and the Issue Price is 3.4 times the face value of equity share.

\*\*The details shall be provided post the fixing of the price band by our Company at the stage of the red herring prospectus or the filing of the price band advertisement.

^ As per restated financials of the period ended March 31, 2024.

The trading price of the Equity Shares could decline due to the factors mentioned in the section "Risk Factors" on page 27 and any other factors that may arise in the future and you may lose all or part of your investments.

#### 7. Key Performance Indicators:

(Rs. In Lakhs except percentages and ratios)

Key Performance Indicator	For the year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Revenue from Operations	2,527.17	2,214.71	2,097.52
Total Income	2,528.96	2,296.24	2,118.67
EBITDA	475.56	268.37	140.85
EBITDA Margin (%)	18.81%	12.12%	6.71%
Profit for the Year/Period	240.41	96.93	10.14
PAT Margin (%)	9.51%	4.38%	0.44%
Return on Net Worth	15.83%	11.25%	1.22%
Return on Capital Employed	14.50%	9.71%	3.99%
Debt-Equity Ratio	0.83	1.31	0.88

#### Notes:

^ Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements.

^ EBITDA is calculated as Profit before tax + Depreciation + Interest Cost - Other Income

^ EBITDA Margin is calculated as EBITDA divided by Total Income

^ PAT Margin is calculated as PAT for the period/year divided by revenue from operations.

^ Net worth means the aggregate value of the paid-up share capital and reserves and surplus of the company.

^ Return on Equity is ratio of Profit after Tax for the period/year divided by Shareholder Equity as at the end of respective period/year.

^ Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as Tangible Net Worth + Total Debt + Deferred Tax Liability.

#### 8. Past Transfer(s)/ Allotment(s)

There have been no secondary sales/ acquisitions of Equity Shares or any convertible securities equivalent to or exceeding 5% of the fully diluted paid up share capital of the Company (calculated on the date of completion of the sales), whether in a single transaction or a group of transactions during the 18 months preceding the date of the Draft Red Herring Prospectus or the Red Herring Prospectus. The Company has not undertaken any primary/ new issuance of Equity Shares or any convertible securities, whether in a single transaction or a group of transactions during the 18 months preceding the date of the Draft Red Herring Prospectus or the Red Herring Prospectus.

#### 9. The Issue price is [-] times of the face value of the Equity Shares.

The Issue Price of ₹ [-] has been determined by our Company in consultation with the BRLM, on the basis of demand from investors for Equity Shares through the Book Building Process and, is justified in view of the above qualitative and quantitative parameters. Investors should read the above-mentioned information along with "Risk Factors", "Our Business", and "Financial Statements" on pages 27, 101 and 160, respectively of the Red Herring Prospectus, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in the "Risk Factors" and you may lose all or part of your investments.

For further details, please see the chapter titled "Basis for Issue Price" beginning on page 86 of the RHP.

## BID/ISSUE PROGRAM

### ANCHOR INVESTOR BIDDING DATE<sup>(1)</sup>: THURSDAY, JUNE 20, 2024

### BID/ISSUE OPENS ON<sup>(1)</sup>: FRIDAY, JUNE 21, 2024

### BID/ISSUE CLOSES ON: TUESDAY, JUNE 25, 2024

<sup>(1)</sup>Our Company in consultation with the BRLM may consider participation by Anchor Investors. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/ Issue Opening Date in accordance with the SEBI (ICDR) Regulations, 2018.

In case of any revisions in the Price Band, the Bid/ Issue Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/ Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum of three Working Days, subject to the Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI (ICDR) Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI (ICDR) Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI (ICDR) Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 216 of Red Herring Prospectus.

Bidders/ Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/ Applicants may be deemed to have authorized the Depositories/ Registrar to the Issue, any requested Demographic Details of the Bidders/ Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/ Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/ Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/ Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active.

Continued to next page.



Continued from previous page...

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 135 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company.

LIABILITY OF MEMBERS AS PER MOA: The Liability of the members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them. AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The Authorized share Capital of the Company is Rs. 14, 00, 00,000/- (Rupees Fourteen Crore only) divided into 1,40,00,000 (One Crore forty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company.

LISTING: The Equity Shares issued through the Red Herring Prospectus are proposed to be listed on the NSE EMERGE (SME Platform of NSE). Our Company has received an 'in-principle' approval from the NSE for the listing of the Equity Shares pursuant to letter dated June 10, 2024.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document.

DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE EMERGE ("EMERGE Platform of NSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by NSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue.

ASBA\* Simple, Safe, Smart way of Application- Make use of it!!! Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account...

UPI-Now available in ASBA for Retail Individual Investors (RII)\*\* Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs & RTAs.

ASBA forms can be downloaded from the website of NSE EMERGE ("SME Portal of NSE") \*\*List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. AXIS BANK Limited has been appointed as Sponsor Bank for the Issue.

BOOK RUNNING LEAD MANAGER TO THE ISSUE: GYR Capital Advisors. REGISTRAR TO THE ISSUE: KFINTech. COMPANY SECRETARY AND COMPLIANCE OFFICER: medicamen.

On behalf of Board of Directors For MEDICAMEN ORGANICS LIMITED Sd/- Ms. Varsha Bansal Company Secretary & Compliance Officer. Disclaimers regarding the availability of the Red Herring Prospectus and the Bid Form on the website of the Company.

HINDUJA LEYLAND FINANCE LIMITED Registered Office: Plot No. C-21, Tower C (1-3 Floors), G Block, BKC Bandra (E), Mumbai - 400051, Maharashtra, Corporate Office: No. 27/A, Developed Industrial Estate, Guindy, Chennai-600032, Branch Office: Office No 101, Manikchand Galleria, Deep Bunglow Chowk, Model Colony, Pune 411016

2nd PUBLIC AUCTION SALE NOTICE CUM TENDER FOR SALE OF SECURED ASSET UNDER Rule 8 (6) and 9 (1)

Pursuant to possession taken hereunder by Authorized Officer of the below mentioned secured asset in exercise of the power conferred upon him under the provisions of Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 for the recovery of secured debts of Hinduja Leyland Finance Ltd., for the outstanding amount mentioned here in below in Column No. D and further interest thereon along with cost and charges due from borrowers / co-borrowers.

Table with columns: Borrower(s)/Co-Borrower(s)/Guarantor(s), Details of Secured Asset, Direction, Four Boundaries, Reserve Price (RP) (D), Earnest Money Deposit (EMD) (10% of RP) (E), Date of Property Inspection and Time (F), Auction Date & Time of opening Tenders (G).

AND WHEREAS the Authorized Officer of the Secured Creditor - Hinduja Leyland Finance Limited has decided to dispose of the said secured asset. This notice of sale is published today that the secured asset detailed above will be sold 3rd July 2024 at 5 PM the above prescribed time and schedule at Hinduja Leyland Finance Limited, Office No 101, Manikchand Galleria, Deep Bunglow Chowk, Model Colony, Pune 411016.

The 5 parcels in respect of the secured asset specified herein above in column No. (C) have been stated to the best of the information and knowledge of the undersigned, who shall however not be responsible for any error, misstatement or omission in the said particulars.

ABOVE MENTIONED CASES WHEREIN SALE NOTICE IS ISSUED/PUBLISHED SECOND TIME THEREFORE, THE BORROWER(S)/GUARANTOR(S) ARE HEREBY GIVEN 15 DAYS SALE NOTICE UNDER THE SARFAESI ACT, 2002 (AS PER THE REVISED GUIDELINES IN THE GAZETTE OF INDIA NOTIFICATION DATED 03/11/2016) to pay the sum mentioned as above before the date of auction failing which the immovable property will be auctioned and balance, if any, will be recovered with interest and costs. If the Borrower pays the amount due to Hinduja Leyland Finance Limited, in full before the date of sale, auction is liable to be stopped.

The successful bidder should bear the charges/fee payable for conveyance such as registration fee, stamp duty etc., as applicable as per Law. The sale certificate shall be issued in the name of the purchaser/bidder and will not be issued in the any other name. The purchaser shall bear the stamp duty, registration charges and all other connected fees, duties, taxes etc. in relation to the execution of the sale certificate.

Successful bidder/purchaser will deduct TDS@1% on sale proceeds as per sec. 194(1-A) of the Income Tax, 1961 & deposit the same by furnishing the challan in Form 26QB and submit the original receipt of TDS Certificate to Hinduja Leyland Finance Ltd., (Rs. 50.00 Lacs and above property)

The Authorized Officer reserves the right to reject any or all the bids without furnishing any reasons therefor. This sale notice is also updated / published on website (www.hindujaleylandfinance.com)

Date: 14.06.2024 Sd/- Authorised Officer, Place: Pune For Hinduja Leyland Finance Limited

Equitas Small Finance Bank Ltd (FORMERLY KNOWN AS EQUITAS FINANCE LTD) Registered Office: No.769, Spencer Place, 4th Floor, Phase-II, Anna Salai, Chennai - 600002. DEMAND NOTICE - NOTICE UNDER SECTION 13 (2) OF THE SARFAESI ACT, 2002

Table with columns: SR NO, Name of the Borrower(s) / Guarantor(s), Demand Notice Date and Amount, Description of Secured Asset (Immovable Property). Includes details for Loan / Facility Account No's and Mr. Ashish Dilip Thorat.

Date - 14.06.2024, Place - Pune Authorized officer, Equitas Small Finance Bank Ltd

DEBTS RECOVERY TRIBUNAL PUNE Unit no 307 to 310 3rd floor, Kakade Biz Icon Building, Shivaji Nagar, Pune 411005. Case No.: 04/1143/2020

Summons under sub-section (4) of section 19 of the Act, read with sub-rule (2A) of rule 5 of the Debt Recovery Tribunal (Procedure) Rules, 1993. PUNJAB NATIONAL BANK VS NOBLE RICHARD

WHEREAS, 04/1143/2020 was listed before Hon'ble Presiding Officer/Registrar on 04/06/2024. WHEREAS this Hon'ble Tribunal is pleased to issue summons/ notice on the said Application under section 19(4) of the Act, (04) filed against you for recovery of debts of Rs. 53590302/- (application along with copies of documents etc. annexed).

- (i) to show cause within thirty days of the service of summons as to why relief prayed for should not be granted; (ii) to disclose particulars of properties or assets other than properties and assets specified by the applicant under serial number 3A of the original application; (iii) you are restrained from dealing with or disposing of secured assets or such other assets and properties disclosed under serial number 3A of the original application, pending hearing and disposal of the application for attachment of properties;

You are also directed to file the written statement with a copy thereof furnished to the applicant and to appear before Registrar on 29/10/2024 at 10:30 A.M failing which the application shall be heard and decided in your absence. Given under my hand and the seal of this Tribunal on this date: 04/06/2024. Note: Strike out whichever is not applicable.

Signature of the Officer Authorised to issue summons.

Aavas Financiers Limited (Formerly known as Au Housing Finance Limited) (CIN: L65922RJ2011PLC034297) Regd. & Corp. Office: 201-202, 2nd Floor, South End Square, Mansarovar Industrial Area, Jaipur. 302020. AUCTION NOTICE

Table with columns: Name of Borrowers/Co-Borrowers/Guarantors/Mortgagors, Dues As on, Date & Amount of Demand Notice, Date of Possession, Description of Property, Reserve Price For Property, Earnest Money For Property, Date & Time of Auction, Place of Tender Submission, Tender Open & Auction at Aavas Financiers Ltd.

Table with columns: Loan No, Name of the Borrower/Co-Borrower/Guarantor(s), Demanded Amount & Date, Nature of possession, Description of the Properties mortgaged, Reserve Price (RP) (A), EMD (10% of RP) (F), Last Date of Submission of Bid (G), Bid incremental Rate (H), Inspection Date & Time, Date of Auction & Time, Known Encumbrances/ Court Case # etc.

\*Together with the further interest @18% p.a. as applicable, incidental expenses, cost, charges etc. incurred upto the date of payment and/or realization thereof. \*\* To the best knowledge and information of the authorized officer of PNB Housing Finance Limited, there are no other encumbrances/claims in respect of above mentioned immovable/secured assets except what is disclosed in the Column No. - K. Further such encumbrances to be catered/paid by the successful purchaser/bidder at his/her end.





THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# MEDICAMEN ORGANICS LIMITED

Corporate Identity Number: U74899DL1995PLC066416

Our Company was incorporated on March 15, 1995 as 'Panchdeep Pharmaceuticals Limited', a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of our Company was changed to 'Medicamen Organics Limited' and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. For details relating to change in the Registered Office of our Company, please refer to "History and Certain Corporate Matters" on page 135 of this RHP.

Registered Office: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India

Contact Number: +91-9818222845; Website: www.medicamenorganics.com;

Contact Person: Ms. Varsha Bansal; E-mail Id: cs@mediorganics.in;

## OUR PROMOTERS: MR. BAL KISHAN GUPTA AND MR. ASHUTOSH GUPTA

INITIAL PUBLIC OFFER OF UPTO 31,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF MEDICAMEN ORGANICS LIMITED (THE "COMPANY" OR "MEDICAMEN" OR "ISSUER") AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ [•] LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1,72,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 29,28,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [•] LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.49 % AND 25.02 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

- QIB PORTION: NOT MORE THAN 50.00% OF THE NET ISSUE • RETAIL PORTION: NOT LESS THAN 35.00% OF THE NET ISSUE
- NON-INSTITUTIONAL PORTION: NOT LESS THAN 15.00% OF THE NET ISSUE • MARKET MAKER PORTION: UP TO 1,72,000 EQUITY SHARES OR 5.54% OF THE ISSUE

**PRICE BAND: ₹ 32 TO ₹ 34 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH**

**THE FLOOR PRICE IS 3.2 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 3.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARES. BIDS CAN BE MADE FOR A MINIMUM OF 4,000 EQUITY SHARES AND IN MULTIPLES OF 4,000 EQUITY SHARES THEREAFTER.**

### RISKS TO INVESTORS

- We require a number of approvals, licenses, registrations and permits in the ordinary course of our business and any failure or delay in obtaining the same in a timely manner may adversely affect our operations.
- The Merchant Banker associated with the Issue has handled 25 public issues in the past two years out of which no issues closed below the Issue Price on Listing date
- Our Company's failure to maintain the quality standards of the products or keep pace with the technological developments could adversely impact our business, results of operations and financial condition.
- The Price/ Earnings ratio based on Diluted EPS for year ended March 2024 for the company at the upper end of the Price Band is 10.69.
- Weighted Average Return on Net worth for Fiscals 2024, 2023 and, 2022 is 11.72%

## BID/ISSUE PROGRAM

**ANCHOR INVESTOR BIDDING DATE<sup>(1)</sup>: THURSDAY, JUNE 20, 2024**

**BID/ ISSUE OPENS ON<sup>(1)</sup>: FRIDAY, JUNE 21, 2024**

**BID/ ISSUE CLOSES ON : TUESDAY, JUNE 25, 2024**

<sup>(1)</sup>Our Company in consultation with the BRLM may consider participation by Anchor Investors. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/ Issue Opening Date in accordance with the SEBI (ICDR) Regulations, 2018.

In case of any revisions in the Price Band, the Bid/ Issue Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/ Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Issue Period for a minimum of three Working Days, subject to the Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Managers and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI (ICDR) Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI (ICDR) Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI (ICDR) Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 216 of Red Herring Prospectus.

Bidders/ Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/ Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/ Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/ Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/ Applicants should ensure that PAN, DP ID and Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/ Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active.

**CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS:** For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 135 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page 257 of the Red Herring Prospectus.

**LIABILITY OF MEMBERS AS PER MOA:** The Liability of the members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.

**AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE:** The Authorized share Capital of the Company is Rs. 14, 00, 00,000/- (Rupees Fourteen Crore only) divided into 1,40,00,000 (One Crore forty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each. For details of the Capital Structure, see "Capital Structure" on the page 62 of the Red Herring Prospectus.

**NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:** Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: 100 equity shares were subscribed by Bal Kishan Gupta, 100 equity shares were subscribed by Lakhwinder Singh Arora, 100 equity shares were subscribed by Virender Kumar, 100 equity shares were subscribed by Ranjit Singh, 100 equity shares were subscribed by Anand Kumar Razdan, 100 equity shares were subscribed by Ashok Nayyar, 100 equity shares were subscribed by Shila Gupta, 100 equity shares were subscribed by Gursharan Arora, and 100 equity shares were subscribed by Tarlochan Singh Sarma Equity Shares of Rs. 10/- Each. Details of the main objects of the Company as contained in the Memorandum of Association, see "History and Corporate Structure" on page 135 of the Red Herring Prospectus. For details of the share capital and capital structure of the Company see "Capital Structure" on page 62 of the Red Herring Prospectus.

**LISTING:** The Equity Shares issued through the Red Herring Prospectus are proposed to be listed on the NSE EMERGE (SME Platform of NSE). Our Company has received an "in-principle" approval from the NSE for the listing of the Equity Shares pursuant to letter dated June 10, 2024. For the purpose of the Issue, the Designated Stock Exchange shall be NSE Limited (NSE). A signed copy of the Red Herring Prospectus has been delivered for registration to the ROC on June 13, 2024 and Prospectus shall be delivered for filing to the ROC in accordance with Section 26(4) of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/ Issue Closing Date, see "Material Contracts and Documents for Inspection" on page 257 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"):** Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI on page 196 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF NSE (THE DESIGNATED STOCK EXCHANGE):** It is to be distinctly understood that the permission given by NSE EMERGE ("EMERGE Platform of NSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by NSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE.

**GENERAL RISK:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 27 of the Red Herring Prospectus.

2. Under Capital Structure Shareholding Pattern of the Company on page no. 66 and wherever appearing in the Red Herring Prospectus dated June 13, 2024 shall be read as follows:

Category (I)	Category of Shareholder (II)	Number of Shareholders (III)	Number of fully paid up Equity Shares held (IV)	Number of Partly paid-up Equity Shares held (V)	Number of shares underlying Depository Receipts (VI)	Total number of Equity Shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total number of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Rights held in each class of securities (IX)		Number of Equity Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted Equity Share capital) (XI) = (VII) + (X) As a % of (A+B+C2)	Number of Locked in Equity Shares (XII)		Number of Equity Shares pledged or otherwise encumbered (XIII)		Number of Equity Shares held in dematerialized form (XIV)
								Class eg: Equity Shares	Class eg: Others			Number (a)	As a % of total Equity Shares held (b)	Number (a)	As a % of total Equity Shares held (b)	
(A)	Promoters and Promoter Group	5	69,83,900	81.21	-	69,83,900	81.21	69,83,900	-	-	-	-	-	-	-	69,83,900
(B)	Public	35	16,16,100	18.79	-	16,16,100	18.79	16,16,100	-	-	-	-	-	-	-	16,16,100
(C)	Non-Promoter- Non Public	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(C)(1)	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(C)(2)	Shares held by Employee Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	<b>Total (A) + (B) + (C)</b>	<b>40</b>	<b>86,00,000</b>	<b>100.00</b>	<b>-</b>	<b>86,00,000</b>	<b>100.00</b>	<b>86,00,000</b>	<b>-</b>	<b>86,00,000</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>86,00,000</b>

3. Under Capital Structure page no. 68 and wherever appearing in the Red Herring Prospectus dated June 13, 2024 revised information is as follows:

As on the date of this Red Herring Prospectus, our Company has a total of Forty (40) Shareholders.

**ASBA\***

Simple, Safe, Smart way of Application- Make use of it!!!

\*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, Investors can avail the same. For details, check section on ASBA below.

Mandatory in Public Issues from January 01, 2016. No cheque will be accepted.

**UPI**

UPI-Now available in ASBA for Retail Individual Investors (RII)\*\*

Investors are required to ensure that the bank account used for bidding is linked to their PAN. UPI - Now available in ASBA for RBIs applying through Registered Brokers, DPs & RTAs. RBIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Investors have to apply through the ASBA process. \*ASBA has to be availed by all the investors except anchor investor. UPI may be availed by Retail Individual Investors. For details on the ASBA and the UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page 216 of the Red Herring Prospectus. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document.

\*ASBA forms can be downloaded from the website of NSE EMERGE ("SME Portal of NSE")

\*\*List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. AXIS BANK Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll free number-18001201740 and Mail id-ipo.upi@npci.org.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in. For issue related grievance investors may contact: GYR Capital Advisors Private Limited -Mr. Mohit Baid (+91 87775 64648) (Email Id: investors@gyrcapitaladvisors.com).

Continued to next page...

Ahmedabad



Continued from previous page...

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <p><b>GYR CAPITAL ADVISORS PRIVATE LIMITED</b> 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad -380 054, Gujarat, India. Telephone: +91 8777564648, Facsimile: N.A. E-mail: info@gyrcapitaladvisors.com, Website: www.gyrcapitaladvisors.com Investor grievance: investors@gyrcapitaladvisors.com Contact Person: Mohit Baid SEBI Registration Number: INM000012810</p>	 <p><b>KFIN TECHNOLOGIES LIMITED</b> Selenium Tower- B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana, India. Tel No.: +91 40 6716 2222 Fax: +91 40 2343 1551 Website: www.kfintech.com, Email: nvl ipo@kfintech.com; Investor Grievance Email: einward.ris@kfintech.com Contact Person: Mr. M Murali Krishna SEBI Registration No.: INR00000221</p>	 <p>Ms. Varsha Bansal, is the Company Secretary and Compliance Officer of our Company. His contact details are set forth hereunder. 10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, 110052, India. Telephone: +91-9818222845, Facsimile: N.A. E-mail: cs@mediorganics.in</p> <p>Investors can contact the Company Secretary and Compliance Officer or the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.</p>
<p><b>AVAILABILITY OF RED HERRING PROSPECTUS:</b> Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a>, website of the Company at <a href="https://www.medicamenorganics.com/investor-corner/">https://www.medicamenorganics.com/investor-corner/</a>, the website of the BRLM to the Issue at <a href="https://www.nseindia.com/companies-listing/corporate-filings-offer-documents">https://www.nseindia.com/companies-listing/corporate-filings-offer-documents</a>, respectively.</p> <p><b>AVAILABILITY OF BID-CUM-APPLICATION FORMS:</b> Bid-Cum-Application forms can be obtained from the Registered Office of the Company: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India; Telephone: +91-9818222845; BRLM: GYR Capital Advisors Private Limited, Telephone: +91 87775 64648 and the Syndicate Member: GYR Capital Advisors Private Limited, Telephone: +91 87775 64648 and the Sub Syndicate Member: Eureka Stock &amp; Share Broking Services Limited, Telephone: 033 66280000 (131) and the Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-application Forms will also be available on the website of NSE EMERGE and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.</p> <p><b>ESCRROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK:</b> AXIS BANK LIMITED <b>UPI:</b> Retail Individual Bidders can also Bid through UPI Mechanism. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.</p>		
<p style="text-align: right;"><b>On behalf of Board of Directors</b> <b>For MEDICAMEN ORGANICS LIMITED</b> Sd/- <b>Ms. Varsha Bansal</b> Company Secretary &amp; Compliance Officer</p>		
<p><b>Place:</b> Delhi <b>Date:</b> June 19, 2024</p> <p><b>Disclaimer:</b> MEDICAMEN ORGANICS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the RHP with the Registrar of Companies, Delhi and Haryana situated at Delhi on June 13, 2024 and thereafter with SEBI and the Stock Exchange. Full copy of the Red Herring Prospectus is available on the website of the SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a>, website of the Company at <a href="https://www.medicamenorganics.com/investor-corner/">https://www.medicamenorganics.com/investor-corner/</a>, the website of the BRLM to the Issue at <a href="https://www.gyrcapitaladvisors.com">www.gyrcapitaladvisors.com</a>, the website of NSE Emerge at <a href="https://www.nseindia.com/companies-listing/corporate-filings-offer-documents">https://www.nseindia.com/companies-listing/corporate-filings-offer-documents</a>, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 27 of the Red Herring Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933 and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act, 1933 and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.</p>		

**"IMPORTANT"**

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

**TATA**  
**TATA POWER**  
(Corporate Contracts Department)

The Tata Power Company Limited, Smart Center of Procurement Excellence, 2<sup>nd</sup> Floor, Sahar Receiving Station, Near Hotel Leela, Sahar Airport Road Andheri (E), Mumbai 400 059, Maharashtra, India  
(Board Line: 022-67173917) CIN: L28290MH1919PLC000567

**NOTICE INVITING TENDER (NIT)**

The Tata Power Company Limited invites tenders from eligible vendors for the following package (Two Part Bidding) in Transmission division, Mumbai.

- Supply and Services for Protection, Automation, Communication and Metering system for new Power Transformers at Trombay Station-A, Mumbai (Package Reference No.-CC25NP016).

For downloading the Tender documents (including procedure for participation in tender) for above tenders, please visit Tender section on website <https://www.tatapower.com> Last day for paying the tender fees and submission of authorization letter is 1500 hrs of 28<sup>th</sup> June 2024 for above tender. Also, all future corrigendum's (if any), to the above tenders will be informed on Tender section on website <https://www.tatapower.com> only.

This advertisement is for information purposes not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the letter of offer dated May 25, 2024 the "Letter of Offer" or ("LOF") filed with the National Stock Exchange of India Limited (NSE), and the Securities and Exchange Board of India ("SEBI").

**MANGALAM GLOBAL ENTERPRISE LIMITED**

Corporate Identification Number: L24224GJ2010PLC062434  
Registered Office: 101, Mangalam Corporate House, 42, Shrimali Society, Netaji Marg, Mithakhali, Navrangpura, Ahmedabad, Gujarat, India, 380009. Website: [www.grouppmangalam.com](http://www.grouppmangalam.com); E-Mail: [cs@grouppmangalam.com](mailto:cs@grouppmangalam.com); Telephone No: +91 79 61615000  
Company Secretary and Compliance Officer: Dashang Manharlal Khatri

Mangalam Global Enterprise Limited bearing Corporate Identification Number L24224GJ2010PLC062434 was incorporated as "Hindprakash Colourchem Private Limited" under the Companies Act, 1956 on September 27, 2010 by Assistant Registrar of Companies Ahmedabad. Further, name of the Company was changed to Mangalam Global Enterprise Private Limited and a Fresh Certificate of Incorporation consequent to change of name was issued on July 31, 2014 by Registrar of Companies, Ahmedabad. Further, Company was converted in to Public Limited Company and the name of the Company was changed to "Mangalam Global Enterprise Limited" and a Fresh Certificate of Incorporation consequent upon conversion of Company from Private Limited to Public Limited dated September 30, 2019 was issued by Registrar of Companies, Ahmedabad. The Company was then listed and admitted to dealings on the Emerge platform of National Stock Exchange of India Limited ("NSE") on November 27, 2019. The company was subsequently migrated from the Emerge Platform to the Main Board of the National Stock Exchange (NSE) on December 23, 2020.

**OUR PROMOTERS: MR. VIPIN PRAKASH MANGAL, MR. CHANAKYA PRAKASH MANGAL AND MR. CHANDRAGUPT PRAKASH MANGAL**

RIGHT ISSUE OF UPTO 2,05,97,225 EQUITY SHARES OF FACE VALUE OF ₹ 2.00 EACH ("EQUITY SHARES" OR "RIGHTS EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹ 20 PER RIGHTS EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 18 PER RIGHTS EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING UP TO ₹ 4,19,45 LAKHS ("THE ISSUE") ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 1 RIGHTS EQUITY SHARES FOR EVERY 7 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY ON THE RECORD DATE, THAT IS FRIDAY, MAY 24, 2024 (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 118. THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARES IS 10 TIMES THE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE REFER TO THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 118 OF THIS LETTER OF OFFER.

**BASIS OF ALLOTMENT**

The Board of Directors of our Company thanks to all its shareholders and investors for their response to the Company's Rights issue of equity Shares, which opened for subscription on Monday, June 03, 2024 and closed on Wednesday, June 12, 2024 and the last date for an Market Renunciation of rights entitlements was Friday, June 07, 2024. Out of total 1000 Application for 21874881 Right Equity Shares 275 Application for 253599 Rights Equity Shares, were rejected due to technical reasons as discussed in the letter of offer. The total number of valid applications received were 725 for 21621282 Rights Equity Shares which was 104.97% total issue size. In accordance with the Letter of offer and the Basis of allotment finalized on Friday, June 14, 2024 in Consultation with National Stock Exchange of India Limited ("NSE") the designated Stock Exchange and the Registrar to the Issue. The Management committee of the Company on Friday, June 14, 2024 has approved the allotment of 20597225 Rights Equity Shares to the successful applicants. In the issue, NIL Rights Equity Shares have been kept in abeyance. All valid Application after technical rejections have been considered for allotment.

**1. The Break-up of valid applications received through ASBA (after technical rejections) is given below :-**

Applicants	Number of Valid applications received	No. of Rights Equity Shares accepted and allotted against Right entitlement		Total Rights Equity Shares accepted and allotted (A+B)
		(A)	(B)	
Eligible Equity Shareholder	872	10979393	9575484	20554877
Renounees	128	42348	-	42348
<b>Total</b>	<b>1000</b>	<b>11021741</b>	<b>9575484</b>	<b>20597225</b>

**2. Information regarding applications received (including ASBA applications):**

Category	Gross			Less: Rejections/Partial Amount			Valid		
	Applications	Equity Shares	Amount (₹)	Applications	Equity Shares	Amount (₹)	Applications	Equity Shares	Amount (₹)
Eligible Equity Shareholders	872	11707273	234145460.00	275	253599	5071980.00	597	11453674	229073480.00
Renounees	128	10167608	203352160.00	0	0	0.00	128	10167608	203352160.00
<b>Total</b>	<b>1000</b>	<b>21874881</b>	<b>437497620.00</b>	<b>275</b>	<b>253599</b>	<b>5071980.00</b>	<b>725</b>	<b>21621282</b>	<b>43225640.00</b>



**Intimations for allotment/refund/rejected cases:** The dispatch of allotment advice cum refund intimation to the investors and intimation for rejection, as applicable, has been completed on June 19, 2024. The instruction for unblocking of funds in case of ASBA were issued to SCSBs on June 14, 2024 NA. The Listing application was filed with NSE on June 15, 2024. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of allotment in dematerialized form has been completed on June 19, 2024. For further details see "Terms of the issue-Allotment advice/refund orders" On Page 132 of the letter of offer. The trading in the Rights Equity Shares issued in the Right issue shall commence on NSE upon receipt of trading permission. The trading is expected to commence on or about June 21, 2024. Further, in accordance with SEBI circular bearing reference-SEBI/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights entitlements has been sent to NSDL and CDSL on June 18, 2024.

**INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN THE DEMATERIALIZED FORM.**

**DISCLAIMER CLAUSE OF SEBI:** It is to be distinctly understood that the submission of Letter of Offer to SEBI should not, in anyway, deemed or construed that the Letter of Offer has been cleared or approved by SEBI.

**DISCLAIMER CLAUSE OF NSE (Designated Stock Exchange):** "It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the letter of offer. The investors are advised to refer to the letter of offer for the full text of the "Disclaimer Clause of NSE".

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.**

REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <p><b>LINK INTIME INDIA PRIVATE LIMITED</b> Address: C-101, 1st Floor, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083, Maharashtra, India Contact person: Ms. Shanti Gopalakrishnan Tel: +91 22 4918 6200; Fax: +91 22 4918 6195 E-mail ID: <a href="mailto:mangalamglobalrights@linkintime.co.in">mangalamglobalrights@linkintime.co.in</a>; Website: <a href="http://www.linkintime.co.in">www.linkintime.co.in</a> SEBI registration number: INR000004058 Investor grievance e-mail: <a href="mailto:mangalamglobalrights@linkintime.co.in">mangalamglobalrights@linkintime.co.in</a> CIN: U67190MH1999PTC118368</p>	 <p><b>MANGALAM GLOBAL ENTERPRISE LIMITED</b> Company Secretary and Compliance Officer: Mr. Dashang Manharlal Khatri Address: 101, Mangalam Corporate House, 42, Shrimali Society, Netaji Marg, Mithakhali, Navrangpura, Ahmedabad-380009, Gujarat, India. Email ID: <a href="mailto:cs@grouppmangalam.com">cs@grouppmangalam.com</a> Contact Number: +91-079 61615000</p>
<p>Investors may contact the Registrar or our Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), e mail address of the sole first holder, folio number or demat account number, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photo copy of the acknowledgement slip. For details on the ASBA process see "Terms of the Issue" beginning on page 118.</p> <p style="text-align: right;"><b>Mangalam Global Enterprise Limited</b> SD/- <b>Dashang Manharlal Khatri</b> Company Secretary and Compliance Officer</p> <p><b>Date:-</b> 19/06/2024 <b>Place:-</b> Ahmedabad</p> <p>Disclaimer: Our Company is proposing subject to receipt of requisite approvals, market conditions and other considerations, a right issue of its Equity Shares and has in this regard filed a Letter of Offer dated May 25, 2024 with SEBI and National Stock Exchange of India Limited. The LOF is available on the website of SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a>, website of the Stock Exchange i.e. National Stock Exchange of India Limited at <a href="http://www.nseindia.com">www.nseindia.com</a> and on the website of Registrar i.e. <a href="http://www.linkintime.co.in">www.linkintime.co.in</a>. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 22 of the LOF. The announcement does not constitute an offer of Right Entitlements of Right Equity Shares for sale in any Jurisdiction, including the United States and any Rights Entitlements and Right Equity Shares described in these announcements may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration. There will be no public offering of Right Equity Shares in the United States.</p>	

**NAMI STEEL PRIVATE LIMITED - IN LIQUIDATION**

CIN: U27100GJ2012PTC071270  
Regd. Add: Survey No. 316-P, 317-P, 342-P & 343-P, Nano Ford Road, Opp. Chharodi Railway Station, Sanand, Ahmedabad, Gujarat - 382110.

Sale of Corporate Debtor as a Going Concern under the Insolvency and Bankruptcy Code, 2016  
**Date and Time of E-Auction:** 19th July, 2024 at 11:00 AM to 2:00 PM  
(With the unlimited extension of 10 minutes each)

Sale of Corporate Debtor as a Going Concern by the liquidator appointed by the Hon'ble National Company Law Tribunal, Ahmedabad Bench vide order dated 23rd April, 2024 in I.A. 1436 OF 2023 IN C.P.(B) No. 236 of 2021. The sale will be done by the undersigned through the E-auction platform <https://eauctions.co.in> (Linkstar Infosys Private Limited)

**Details of the Assets** | **Manner of Sale/Block**

Asset	Manner of Sale/Block
Sale of Nami Steel Private Limited as a Going Concern as per the Regulation 32(e) of the IBC (Liquidation Process) Regulation, 2016 along with all assets including Land & Building, Plant & Machinery and Securities & Financial Assets	Sale as a Going Concern

Reserve Price	Earnest Money Deposit	Incremental Value
₹ 45,00,00,000/-	₹ 4,50,00,000/-	₹ 10,00,000

Last date of submission of Eligibility Documents: 5th July, 2024 in the manner mentioned in detail E-auction Process Document  
Declaration of Eligible Bidder: 8th July, 2024  
Inspection of Assets of Corporate Debtor: From 9th July, 2024 to 16th July, 2024  
Last Date for submission of Earnest Money Deposit: 17th July, 2024  
Date and time of E-Auction for qualified bidders: 19th July, 2024 at 11:00 AM to 2:00 PM

**TERMS & CONDITIONS OF THE SALE IS AS UNDER:**

- E-auction will be conducted on "AS IS WHERE IS", "AS IS WHAT IS", "WHATEVER THERE IS BASIS" AND "NO RECOURSE BASIS" as such sale is without any kind of warranties and indemnities through approved service provider Linkstar Infosys Private Limited Contact person on behalf of E-Auction Agency (Linkstar): Contact person: Mr. Dixit Prajapati Email [admin@eauctions.co.in](mailto:admin@eauctions.co.in), Mobile No: +91 9870099713
- Documents shall be submitted to Liquidator through email and hard copy in the format prescribed in the detailed E-auction Process Document on or before 5th July, 2024 before 05:00 P.M.
- EMD shall be deposited with the Liquidator as prescribed in the detailed E-auction Process Document on or before 17th July, 2024 before 05:00 P.M. The bid form along with detailed terms & conditions of the complete E-auction process can be downloaded from the website <https://eauctions.co.in>.
- It is clarified that this invitation purports to invite prospective bidders and does not create any kind of binding obligation on the part of the Liquidator or the Company to effectuate the sale. The Liquidator reserves the right to cancel or modify the process and/or not to accept and/or disqualify any interested party/potential investor/bidder without assigning any reason and without any liability.
- All the terms and conditions are to be mandatorily referred from the detailed E-Auction Process Document, prior to submission of EMD and participation in the process. The Liquidator can be contacted at [cirpanmistee@gmail.com](mailto:cirpanmistee@gmail.com).

SD/-  
CA Bhavik Haribhai Rupapara  
Liquidator - Nami Steel Private Limited  
Reg. No.: IBBI/PA-001/IP-P/02741/2022-2023/14196  
Email ID: [cirpanmistee@gmail.com](mailto:cirpanmistee@gmail.com), [cabhavikr@gmail.com](mailto:cabhavikr@gmail.com)  
Correspondence Address: SSARVI Resolution Services LLP, B-610, BSEL Tech Park, Sec. 30 A, Vashi, Navi Mumbai-400 705  
Date: 20.06.2024  
Place: Navi Mumbai  
Contact No: +91 9082607703 (Call on WhatsApp)

**BF INVESTMENT LIMITED**

Regd. Off.: Mundhwa, Pune Cantonment, Pune-411036  
CIN : L65993PN2009PLC134021  
Website : [www.bfilpune.com](http://www.bfilpune.com)  
Tel : +91 7719005777  
Email : [Secretarial@bfilpune.com](mailto:Secretarial@bfilpune.com)

**15<sup>th</sup> Annual General Meeting**

Notice is hereby given that the 15<sup>th</sup> Annual General Meeting (AGM) of the members of the Company will be held on Wednesday, July 31, 2024 at 11:00 a.m. (I.S.T.) through Video Conferencing (VC) / Other Audio Visual Means (OAVM), without presence of Members at a common venue, in accordance with the provisions of the Companies Act, 2013, ("the Act") and rules thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended, read with MCA General Circular No. 10/2022 dated December 28, 2022, General Circular No. 09/2023 dated September 25, 2023 respectively and Circular No. SEBI/HO/CFD/PoD-2/P/CIR/2023/167 dated October 07, 2023 read with Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 issued by Securities and Exchange Board of India ("SEBI") (collectively referred to as "MCA and SEBI Circulars"), to transact the business as set out in the Notice convening the 15<sup>th</sup> AGM.

**In connection of the same, kindly note as follows :**

- Notice of the AGM and Annual Report for the Financial Year 2023-24:**
  - will be sent to all Shareholders by email, whose email addresses are registered with the Company / Depository Participant(s) and
  - will also be uploaded on the website of the Company at [www.bfilpune.com](http://www.bfilpune.com), websites of the Stock Exchanges i.e. BSE Limited, [www.bseindia.com](http://www.bseindia.com) and National Stock Exchange of India Limited, [www.nseindia.com](http://www.nseindia.com) and also on the website of National Securities Depository Limited (NSDL) <https://www.evoting.nsdl.com>.
- Manner of registering / updating email addresses :**
  - Shareholders holding shares in Physical Form are requested to provide a signed request letter mentioning Folio No., e-mail id, Name of the Shareholder, self attested copy of PAN Card by email to [pune@linkintime.co.in](mailto:pune@linkintime.co.in) to register their email address and mobile number.
  - Shareholders holding shares in dematerialised form (DEMAT) are requested to register or update their email addresses and mobile number with their relevant depository participant(s).
- Manner of casting vote(s) through e-voting :**
  - Shareholders will have an opportunity to cast their vote(s) through remote e-Voting facility, on all resolutions set out in the Notice of the AGM. This remote e-Voting facility will also be available during the AGM.
  - The detailed instructions for remote e-Voting by shareholders holding shares in dematerialised mode, physical mode and for shareholders who have not registered their e-mail addresses are provided in the Notice of the AGM.
- Book Closure for AGM :**  
The Register of Members and Share Transfer Books of the Company shall remain closed on Wednesday, July 31, 2024 for the purpose of 15<sup>th</sup> AGM.  
This Notice is being issued for the information and benefit of all the Members of the Company in compliance with the applicable circulars of MCA and SEBI. For further information / clarification / assistance in respect of e-Voting and related matters, concern shareholders are requested to contact the Registrar and Transfer Agent of the Company and / or the Company at below mentioned address.

<p>Link Intime India Pvt. Ltd. Unit - BF Investment Limited Block No.202, Akshay Complex, Near Ganesh Temple, off Dhole Patil Road, Pune - 411 001. Maharashtra Tel:+91 20 26160084 / 26161629 Email : <a href="mailto:pune@linkintime.co.in">pune@linkintime.co.in</a></p>	<p>Secretarial Department BF Investment Limited Mundhwa, Pune - 411 036 Tel No. - +91 77190 05777 Email : <a href="mailto:Secretarial@bfilpune.com">Secretarial@bfilpune.com</a></p>
<p><b>For BF Investment Limited</b> SD/- <b>Gayatri Pendse Karandikar</b> Company Secretary</p>	
<p><b>Place:</b> Pune <b>Date:</b> June 19, 2024</p>	

  
**RADICO KHAITAN LIMITED**  
CIN : L26941UP1983PLC027278

Registered Office : Rampur Distillery, Bareilly Road, Rampur - 244 901 (U.P.)  
Tel. No. : 0595-2350601/2, 2351703 Fax No. : 0595-2350009  
Email ID : [investor@radico.co.in](mailto:investor@radico.co.in), Website : [www.radico.khaitan.com](http://www.radico.khaitan.com)

**NOTICE**  
**Transfer of Equity Shares of the Company to Investor Education and Protection Fund ("IEPF")**

This notice is given pursuant to the provisions of section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and subsequent amendments thereto ("Rules").

The said Rules amongst other matters, contain provisions for transfer of shares, in respect of which dividend has not been paid or claimed for seven consecutive years, in the name of Investor Education and Protection Fund Suspense Account ("IEPF Suspense Account"). The Shareholders may note that the shares, in respect of which the dividend declared by the Company for the financial year 2016-17 which remained unclaimed for seven consecutive years, are due for transfer to the IEPF Suspense Account.

Accordingly, individual communication is being sent to all the concerned shareholders at their registered address whose shares are liable to be transferred to IEPF Suspense Account under the aforesaid Rules for taking appropriate action. The details of shareholders whose shares are due for transfer to IEPF Suspense Account are made available on website of the company at [www.radico.khaitan.com](http://www.radico.khaitan.com). The Shareholders may further note that the details uploaded by the Company on its website would be regarded and shall be deemed as adequate Notice in respect of transfer of Shares to the IEPF Suspense Account pursuant to the Rules.

In this connection, concerned members may please note that for members holding shares in physical form, the Company shall issue share certificates in lieu of the original share certificates held by them for the purpose of transfer of shares to IEPF and upon such issue, original share certificates registered in their name shall stand automatically cancelled and for members holding shares in electronic form, the Company shall transfer the shares by way of corporate action through the Depositories to the IEPF Authority.

In order to avoid transfer of shares to IEPF, any member whose name is appearing in the above said list shall send a request letter alongwith requisite documents, on or before September 30, 2024, at the Registered Office address of the Company or Company's Registrar and Transfer Agent, Kfin Technologies Limited ("RTA"), at the address mentioned below.

In case Company does not receive the valid claim from the concerned shareholders on or before September 30, 2024, the Company shall, with a view to comply with requirements set out in the Rules, transfer the shares of the concerned shareholders of IEPF Suspense Account. Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF pursuant to the said Rules after the aforesaid date.

In case of any query the concerned shareholder may contact the Company at [investor@radico.co.in](mailto:investor@radico.co.in) or RTA at Salenium Tower B, Plot 31 & 32, Financial District Nanakramguda , Selingampally Mandal, Hyderabad-500032 Telangana, Toll free no. 1-800-309-4001, Email [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com) Website : [www.kfintech.com](http://www.kfintech.com).

**For Radico Khaitan Limited**  
SD/-  
**Dinesh Kumar Gupta**  
Sr. VP - Legal & Company Secretary

**Place:** New Delhi  
**Date:** 19.06.2024

**CSL Finance Limited** 

CIN: L74899DL1992PLC051462  
Regd. Office: 410-412, 18/12, 4th Floor, W.E.A. Arya Samaj Road, Karol Bagh, New Delhi - 110005  
Corp. office: 716-717, 7th floor, Tower B, World Trade Tower, Noida, Sector-16, U.P.-201301  
Tel: 0120-4290654; Email: [info@csfinance.in](mailto:info@csfinance.in); Web: [www.csfinance.in](http://www.csfinance.in)

**NOTICE FOR COMPULSORY TRANSFER OF UNPAID/UNCLAIMED DIVIDEND & EQUITY SHARES OF THE COMPANY TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF).**

Dear Shareholders(s),

We wish to inform you that pursuant to Section 124(5) and (6) of the Companies Act, 2013 (the "act"), read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer, and Refund) Rules, 2016 as amended from time to time (including any statutory modification(s), enactments(s) thereof for the time being in force) (hereinafter referred to as "IEPF Rules") available on the website of Ministry of Corporate Affairs at [www.iepf.gov.in](http://www.iepf.gov.in) has inter-alia, specified the manner for transfer of Unpaid/Unclaimed Dividend along with the equity shares in respect of which dividend is unpaid or unclaimed for a period of seven years to Investor Education and Protection Fund (IEPF) established by the Central Government. Shareholders who have not claimed their dividend for a period of seven years i.e. from the Financial Year 2016-17 and equity shares on which dividend has not been claimed for seven consecutive years i.e. from the Financial Year 2016-17 is/are liable to be IEPF as provided under the Companies Act, 2013 read with IEPF Rules.

In compliance with the provisions of IEPF Rules read with Secretarial Standard on Dividend (SS-3), the company has uploaded details i.e. Name and Folio No./DPID-CLID of such shareholders whose dividend and equity shares are due for transfer to IEPF on its website [www.csfinance.in](http://www.csfinance.in) under Investors' Information for Shareholders Section. The Company shall initiate the transfer of equity shares to IEPF in respect of which dividend stands unpaid/unclaimed upto 15<sup>th</sup> September, 2024.

We would further like to state that future dividend/benefit, if any, in respect of equity shares so transferred shall also be credited to the IEPF.

Upon transfer of equity shares and unpaid/unclaimed dividend to the IEPF, the claimant can claim those equity shares and unpaid/unclaimed dividend in accordance with the procedure and on submission of necessary forms and documents to the IEPF Authority.

You are also hereby informed that upon transfer of equity shares and unpaid/unclaimed dividend to IEPF, no claim shall lie against the Company/RTA. (IEPF Rules and web-form IEPF-5 for claiming Refund of equity shares and dividend are available on the website of Ministry of Corporate Affairs at [www.iepf.gov.in](http://www.iepf.gov.in).)

In view of the above, you are once again requested to claim your unpaid/unclaimed dividend, if any immediately on or before 15th September, 2024.

**Procedure for claim of unpaid/unclaimed dividend:**

In case shareholders holding equity shares in demat form, please update your bank detail in your demat account and send updated client master along with a request letter to RTA.	In case shareholders holding shares in physical form, please send form ISR-1, copy of PAN/PAN(s) (in case of joint holders), original cancelled cheque (name of 1st holder printed on it) or copy of bank passbook having MICR Code, IFSC and A/c No., duly attested by the Bank Manager, Form ISR-2 (in case of signature mismatch with our records/or missing) and Form SH-13 or Form ISR-3 (which can be downloaded from the Website of RTA i.e. <a href="http://www.masserv.com">www.masserv.com</a> .)
---	---

In this regard the company has also sent letter(s) by ordinary post to the concerned shareholders at their registered address whose shares are liable to be transferred to IEPF Authority.

In case you have any queries on the subject matter, you may contact our Registrar and Share Transfer Agent:

**M/s MAS Services Limited 2-34 2nd Floor, Okhla Industrial Area, Phase-II, New Delhi-110020**  
Tel:





THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# MEDICAMEN ORGANICS LIMITED

CORPORATE IDENTIFICATION NUMBER: U74899DL1995PLC066416

Our Company was incorporated on March 15, 1995 as "Panchdeep Pharmaceuticals Limited", a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of our Company was changed to "Medicamen Organics Limited" and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. For details relating to change in the Registered Office of our Company, please refer to "History and Certain Corporate Matters" on page 136 of this Prospectus.

Registered Office: 10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India;  
Telephone: +91-9818222845; Email: cs@mediorganics.in; Website: www.medicamenorganics.com;  
Contact Person: Ms. Varsha Bansal, Company Secretary & Compliance Officer;

**OUR PROMOTERS: MR. BAL KISHAN GUPTA AND MR. ASHUTOSH GUPTA**

## BASIS OF ALLOTMENT

PUBLIC ISSUE OF 31,00,000 EQUITY SHARES OF FACE VALUE ₹ 10 EACH ("EQUITY SHARES") OF MEDICAMEN ORGANICS LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 34 PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ 24 PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING UP TO ₹ 1054.00 LAKHS (THE "ISSUE"). 1,72,000 EQUITY SHARES AGGREGATING TO ₹ 58.48 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 29,28,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT AN ISSUE PRICE OF ₹ 34 PER EQUITY SHARE AGGREGATING TO ₹ 995.52 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.49 % AND 25.02 % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- AND ISSUE PRICE IS ₹ 34/-**  
**THE ISSUE PRICE IS 3.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARE**  
**ANCHOR INVESTOR ISSUE PRICE: ₹ 34 PER EQUITY SHARE THE ISSUE PRICE IS 3.4 TIMES OF THE FACE VALUE**

## RISKS TO INVESTORS

- We require a number of approvals, licenses, registrations and permits in the ordinary course of our business and any failure or delay in obtaining the same in a timely manner may adversely affect our operations.
- The Merchant Banker associated with the Issue has handled 25 public issues in the past two years out of which no issues closed below the Issue Price on Listing date
- Our Company's failure to maintain the quality standards of the products or keep pace with the technological developments could adversely impact our business, results of operations and financial condition.
- The Price/ Earnings ratio based on Diluted EPS for year ended March 2024 for the company at the upper end of the Price Band is 10.69.
- Weighted Average Return on Net worth for Fiscals 2024, 2023 and, 2022 is 11.72%

## BID/ISSUE PERIOD

**ANCHOR INVESTOR BIDDING DATE WAS: THURSDAY, JUNE 20, 2024**  
**BID/ ISSUE OPENED ON: FRIDAY, JUNE 21, 2024**  
**BID/ ISSUE CLOSED ON: TUESDAY, JUNE 25, 2024**

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 50% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 217 of Prospectus.

The bidding for Anchor Investors opened and closed on June 20, 2024. The Company received 02 Anchor Investor Application Forms from 02 Anchor Investors (including Nil mutual funds through Nil Mutual Fund schemes) for 11,84,000 Equity Shares. The Anchor Investor Allocation price was finalized at Rs. 34/- per Equity Share. A total of 8,76,000 Equity Shares were allotted under the Anchor Investor portion aggregating to Rs. 297.84 Lakhs.

The Issue (excluding Anchor Investors Portion) received 3,58,009 Applications for 2,04,25,80,000 Equity Shares (before technical rejections) resulting in 918.43 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before technical rejections):

### Detail of the Applications Received:

S. No.	Category	No. of Applications* Shares applied	No. of Equity as per Prospectus	Equity Shares Reserved Subscribed	No. of times (in Rs.)	Amount
1.	Retail-Individual Investors	337290	1349160000	10,28,000	1312.41	45,86,77,20,000
2.	Non-Institutional Investors	20656	593848000	4,40,000	1349.65	20,16,19,16,000
3.	Market Maker	1	172000	1,72,000	1.00	58,48,000
4.	Qualified Institutional Buyers (Excluding Anchor Investors)	62	99400000	5,84,000	68.08	3,379,600,000
5.	Anchor Investors	2	1184000	8,76,000	1.35	4,02,56,000
	<b>Total</b>	<b>3,58,011</b>	<b>2,04,37,64,000</b>	<b>31,00,000</b>	<b>659.26</b>	<b>69,47,53,40,000</b>

### Final Demand

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	32	4,736,000	0.19	4,736,000	0.19
2	33	2,828,000	0.12	7,564,000	0.31
3	34	1,628,348,000	66.98	1,635,912,000	67.30
	CUTOFF	795,024,000	32.70	2,430,936,000	100.00
	<b>Total</b>	<b>2,430,936,000</b>	<b>100.00</b>		

The Basis of Allotment was finalised in consultation with the Designated Stock Exchange, being National Stock Exchange of India Limited on June 26, 2024.

### 1) Allotment to Retail Individual Investors (After Technical Rejections)

The Basis of Allotment to the Retail Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 34/- per Equity Share, was finalised in consultation with National Stock Exchange of India Limited. The category has been subscribed to the extent of 109.54 times. The total number of Equity Shares Allotted in this category is 10,28,000 Equity Shares to 2149 successful applicants. The details of the Basis of Allotment of the said category is as under:

No. of Shares Applied for (Category Wise)	No. of application received	% of Total	Total No. of shares applied	% of Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of Shares Allotted
Retail Individual Investor	330384	100.00	1321536000	100.00	4000	13:16712	10,28,000

### 2) Allotment to Non-Institutional Investors (After Technical Rejections)

The Basis of Allotment to the Non-Institutional Investors, who have Bid at cut-off Price or at or above the Issue Price of Rs. 34/- per Equity Share, was finalised in consultation with National Stock Exchange of India Limited. The category has been subscribed to the extent of 270.88 times. The total number of Equity Shares Allotted in this category is 4,40,000 Equity Shares to 718 successful applicants. The details of the Basis of Allotment of the said category is as under (Sample Basis):

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/ allotted	Surplus/ Deficit (B)-(6)
-1	-2	-3	-4	-5	-6	-7	-8	-9
8000	12576	62.45	100608000	17.21	75723	19	12576	76000
12000	2338	11.61	28056000	4.60	21116	5	2338	20000
16000	672	3.34	10752000	1.84	8093	1	336	8000
1392000	2	0.01	2784000	0.48	2095	1	2	4000
1408000	2	0.01	2816000	0.48	2119	1	2	4000
1420000	2	0.01	2840000	0.49	2138	1	2	4000
1432000	8	0.04	11456000	1.96	8622	1	4	8000
1440000	2	0.01	2880000	0.49	2168	1	2	4000
1444000	2	0.01	2888000	0.49	2174	1	2	4000
1456000	2	0.01	2912000	0.50	2192	1	2	4000
1464000	2	0.01	2928000	0.50	2204	1	2	4000
1468000	45	0.22	66060000	11.30	49720	13	45	52000

### 3) Allotment to QIBs excluding Anchor Investors (After Technical Rejections)

Allotment to QIBs, who have bid at the Issue Price of Rs. 34/- per Equity Share or above, has been done on a proportionate basis in consultation with National Stock Exchange of India Limited. This category has been subscribed to the extent of 108.63 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 5,84,000 Equity Shares, which were allotted to 73 successful +

### Applicants.

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/ allotted	Surplus/ Deficit (B)-(6)
-1	-2	-3	-4	-5	-6	-7	-8	-9
584000	3	4.84	1752000	1.76	10294	1	1	12000
588000	1	1.61	588000	0.59	3455	1	1	4000
736000	1	1.61	736000	0.74	4324	1	1	4000
888000	1	1.61	888000	0.89	5217	1	1	4000
936000	1	1.61	936000	0.94	5499	1	1	4000
1160000	1	1.61	1160000	1.17	6815	1	1	8000
1168000	15	24.19	17520000	17.63	102934	1	1	60000
						11	15	44000
1284000	1	1.61	1284000	1.29	7544	1	1	8000
1400000	1	1.61	1400000	1.41	8225	1	1	8000
1440000	1	1.61	1440000	1.45	8460	1	1	8000
1524000	1	1.61	1524000	1.53	8954	1	1	8000
1528000	1	1.61	1528000	1.54	8977	1	1	8000
1768000	2	3.23	3536000	3.56	20775	1	1	16000
						1	2	4000
1880000	1	1.61	1880000	1.89	11046	1	1	12000
1908000	2	3.23	3816000	3.84	22420	1	1	24000
2028000	3	4.84	6084000	6.12	35745	1	1	36000
2040000	1	1.61	2040000	2.05	11986	1	1	12000
2048000	3	4.84	6144000	6.18	36098	1	1	36000
2052000	22	35.48	45144000	45.42	265232	1	1	264000
<b>TOTAL</b>	<b>62</b>	<b>100.00</b>	<b>99400000</b>	<b>100.00</b>	<b>584000</b>			<b>584000</b>

### 4) Allotment to Anchor Investors (After Technical Rejections)

The Company in consultation with the BRLM has allocated 8,76,000 Equity Shares to 2 Anchor Investors at the Anchor Investor Issue Price of Rs. 34/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

Category	Fis/BANKS	MF's	IC	AIF	FIs/FPIs	NBFC'S	TOTAL
Anchor	-	-	-	4,32,000	-	4,44,000	8,76,000

### 5) Allotment to Market Maker (After Technical Rejections)

The Basis of Allotment to Market Maker who have bid at an Issue Price of Rs 34/- per Equity Share or above, was finalised in consultation with NSE. The category was subscribed by 1.00 times i.e. for 1,72,000 Equity Shares the total number of shares allotted in this category is 1,72,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of Application Received	% of Total	Total No. of Shares Applied in each Category	% to Total	Total No. of Shares Allotted	Ratio
1,72,000	1	100	1,72,000	100	1,72,000	1
<b>Total</b>	<b>1</b>	<b>100</b>	<b>1,72,000</b>	<b>100</b>	<b>1,72,000</b>	<b>1</b>

The Board of Directors of our Company at its meeting held on June 26, 2024 has taken on record the basis of allotment of Equity Shares approved by the designated stock exchange, being National Stock Exchange of India Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs shall be dispatched/ mailed for unblocking of funds and transfer to the Public Issue Account on or before June 27, 2024 and payment to non-Syndicate brokers shall be issued on June 27, 2024. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before June 27, 2024 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from National Stock Exchange of India Limited and the trading of the Equity Shares is expected to commence on June 28, 2024.

**Note:** All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated June 26, 2024 filed with the Registrar of Companies, Delhi and Haryana ("RoC").

## INVESTORS, PLEASE NOTE

The details of the allotment made has been hosted on the website of the Registrar to the Issue, KFINTECH LIMITED at website: <https://www.kfintech.com/>

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>GYR CAPITAL ADVISORS PRIVATE LIMITED</b> Address: 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad - 380 054, Gujarat, India. Telephone: +91 87775 64648 Facsimile: N.A. E-mail: info@gyrcapitaladvisors.com Website: www.gyrcapitaladvisors.com Investor grievance: investors@gyrcapitaladvisors.com Contact Person: Mohit Baid SEBI Registration Number: INM000012810 CIN: U67200GJ2017PTC096908	 <b>KFIN TECHNOLOGIES LIMITED</b> Selenium Tower-B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana, India. Tel No.: +91 40 6716 2222 Facsimile: N.A. Fax: +91 4023431551 Email: nvl ipo@kfintech.com Website: www.kfintech.com Investor grievance: investors@gyrcapitaladvisors.com Investor Grievance Email: einward.ris@kfintech.com Contact Person: Mr. M Murali Krishna SEBI Registration No.: INR000002221	 <b>Ms. Varsha Bansal</b> , is the Company Secretary and Compliance Officer of our Company. His contact details are set forth hereunder: 10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, 110052, India. Telephone: +91-9818222845, Facsimile: N.A. E-mail: cs@mediorganics.in Investors can contact the Company Secretary and Compliance Officer of the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc.

Place: Delhi  
Date: June 26, 2024

**Disclaimer:** MEDICAMEN ORGANICS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Delhi on June 26, 2024 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of NSE Emerge at [https://www1.nseindia.com/emerget/index\\_sme.htm](https://www1.nseindia.com/emerget/index_sme.htm) and is available on the websites of the BRLM at [www.gyrcapitaladvisors.com](http://www.gyrcapitaladvisors.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors" beginning on page 27 of the Prospectus.  
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.

On behalf of Board of Directors  
For MEDICAMEN ORGANICS LIMITED  
Sd/-  
Ms. Varsha Bansal  
Company Secretary & Compliance Officer